Business Wire

The Bureau International des Expositions (BIE) announces the official list of candidates for Specialised Expo 2022/23: Poland (Łódź), United States (Minneapolis), Brazil (Rio de Janeiro) and Argentina (Buenos Aires)

15.12.2016 21:14 | Business Wire

Del

The Bureau International des Expositions (BIE) has closed the candidature period for Specialised Expo 2022/23. Four countries have submitted competing bids to organise Specialised Expo 2022/23: the Republic of Poland, the United States of America, the Federative Republic of Brazil and the Republic of Argentina.

The 169 Member States of the BIE will elect the host country of Specialised Expo 2022/23 at the 162nd General Assembly in November 2017.

Poland’s bid is for a Specialised Expo in the city of Łódź between 15 June and 15 September 2022 under the theme “City Re:Invented.”

The United States’ bid is for a Specialised Expo in Minneapolis between 15 May and 15 August 2023 under the theme “Wellness and Well Being for All: Healthy People, Healthy Planet.” The United States is not a Member State of the BIE.*

Brazil’s bid is for a Specialised Expo in Rio de Janeiro between 4 March and 27 May 2022 under the theme “Metropolitan Cities and Sustainability: Cross Border Potentials.”

Argentina’s bid is for a Specialised Expo in Buenos Aires between 15 January and 15 April 2023 under the theme “Science, Innovation, Art and Creativity for the Human Development.”

The Secretary General of the BIE, Vicente G. Loscertales, stated that “these four candidatures demonstrate a high level of interest for this type of Expo.” The project examination phase for Specialised Expo 2022/23 will take place over the next few months. Each candidate will submit a bid dossier, to be followed by a BIE Enquiry Mission. The projects will then be presented to the General Assembly of the BIE on 14 June 2017. The election of the host country by the 169 Member States of the BIE will take place at the subsequent General Assembly in November 2017.

Specialised Expos, known officially as International Recognised Exhibitions, can be organised in the interval between two World Expos. They can last up to three months and are designed to respond to a precise challenge facing humanity. The most recent Specialised Expo was held in the city of Yeosu in the Republic of Korea in 2012, which attracted over 8 million visitors under the theme “The Living Ocean and Coast”. The next Specialised Expo is to take place in Astana, the capital of Kazakhstan, between 10 June and 10 September 2017 under the theme “Future Energy”.

* In accordance with BIE regulations, Member States must be given priority over non-Member States.

The Bureau International des Expositions (BIE) is the intergovernmental organisation embodying the commitment of its 169 member States to lead, promote and foster International Exhibitions for the benefit of the citizens of the international community.

The BIE oversees four types of International Exhibitions: World Expos (International Registered Exhibitions), Specialised Expos (International Recognised Exhibitions), Horticultural Expos and the Triennale di Milano.

International Exhibitions are global events dedicated to finding solutions to specific challenges facing humanity by offering a journey inside the Expo theme through engaging and immersive activities.

Contact information

Bureau International des Expositions (BIE)
Antoine Bourdeix
media@bie-paris.org - Tel: + 33(0)1 45 00 38 63
www.bie-paris.org - Twitter/Facebook : bieparis

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 07:08Pressemelding

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom